{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "COVID-19",
      "ORF3a",
      "Phase III vaccine trials",
      "Pre-fusion S protein",
      "SARS-CoV-2 vaccine",
      "Vaccine platform"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "33482248",
  "DateCompleted": {
    "Year": "2021",
    "Month": "05",
    "Day": "19"
  },
  "DateRevised": {
    "Year": "2023",
    "Month": "11",
    "Day": "10"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2021",
        "Month": "01",
        "Day": "20"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1016/j.addr.2021.01.014",
      "S0169-409X(21)00024-7"
    ],
    "Journal": {
      "ISSN": "1872-8294",
      "JournalIssue": {
        "Volume": "172",
        "PubDate": {
          "Year": "2021",
          "Month": "May"
        }
      },
      "Title": "Advanced drug delivery reviews",
      "ISOAbbreviation": "Adv Drug Deliv Rev"
    },
    "ArticleTitle": "SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?",
    "Pagination": {
      "StartPage": "314",
      "EndPage": "338",
      "MedlinePgn": "314-338"
    },
    "Abstract": {
      "AbstractText": [
        "The ongoing SARS-CoV-2 pandemic has led to the focused application of resources and scientific expertise toward the goal of developing investigational vaccines to prevent COVID-19. The highly collaborative global efforts by private industry, governments and non-governmental organizations have resulted in a number of SARS-CoV-2 vaccine candidates moving to Phase III trials in a period of only months since the start of the pandemic. In this review, we provide an overview of the preclinical and clinical data on SARS-CoV-2 vaccines that are currently in Phase III clinical trials and in few cases authorized for emergency use. We further discuss relevant vaccine platforms and provide a discussion of SARS-CoV-2 antigens that may be targeted to increase the breadth and durability of vaccine responses."
      ],
      "CopyrightInformation": "Copyright \u00a9 2021 The Authors. Published by Elsevier B.V. All rights reserved."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA, USA."
          }
        ],
        "LastName": "Chakraborty",
        "ForeName": "Saborni",
        "Initials": "S"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Institute for Immunity, Transplantation, and Infection, Stanford University, Stanford, CA, USA."
          }
        ],
        "LastName": "Mallajosyula",
        "ForeName": "Vamsee",
        "Initials": "V"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Infectious Disease Initiative, Chan Zuckerberg Biohub, San Francisco, CA, USA."
          }
        ],
        "LastName": "Tato",
        "ForeName": "Cristina M",
        "Initials": "CM"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "J. Craig Venter Institute, 4120 Capricorn Lane, La Jolla, CA 92037, USA; Department of Infectious Diseases, University of California San Diego, La Jolla, CA 92037, USA."
          }
        ],
        "LastName": "Tan",
        "ForeName": "Gene S",
        "Initials": "GS"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA, USA; Department of Microbiology and Immunology, Stanford University, Stanford, CA, USA; Chan Zuckerberg Biohub, San Francisco, CA, USA. Electronic address: taiawang@stanford.edu."
          }
        ],
        "LastName": "Wang",
        "ForeName": "Taia T",
        "Initials": "TT"
      }
    ],
    "GrantList": [
      {
        "GrantID": "R01 AI125567",
        "Acronym": "AI",
        "Agency": "NIAID NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "R01 AI139119",
        "Acronym": "AI",
        "Agency": "NIAID NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "U19 AI111825",
        "Acronym": "AI",
        "Agency": "NIAID NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "U54 CA260517",
        "Acronym": "CA",
        "Agency": "NCI NIH HHS",
        "Country": "United States"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, N.I.H., Extramural",
      "Research Support, Non-U.S. Gov't",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Netherlands",
    "MedlineTA": "Adv Drug Deliv Rev",
    "NlmUniqueID": "8710523",
    "ISSNLinking": "0169-409X"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "COVID-19 Vaccines"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Animals"
    },
    {
      "QualifierName": [
        "epidemiology",
        "immunology",
        "prevention & control"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [
        "administration & dosage",
        "chemistry",
        "immunology"
      ],
      "DescriptorName": "COVID-19 Vaccines"
    },
    {
      "QualifierName": [
        "methods"
      ],
      "DescriptorName": "Clinical Trials, Phase III as Topic"
    },
    {
      "QualifierName": [
        "methods",
        "trends"
      ],
      "DescriptorName": "Drug Evaluation, Preclinical"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Protein Structure, Secondary"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Protein Structure, Tertiary"
    },
    {
      "QualifierName": [
        "chemistry",
        "drug effects",
        "immunology"
      ],
      "DescriptorName": "SARS-CoV-2"
    }
  ],
  "CoiStatement": "Declaration of Competing Interest The authors have no competing interests to declare."
}